(51) International Patent Classification 6:
C12N 15/12, 15/11, 15/70, 1/21, C12Q 1/68, C07K 14/47, 16/18, A61K 38/17

(11) International Publication Number: WO 98/36069
(43) International Publication Date: 20 August 1998 (20.08.98)

(21) International Application Number: PCT/US98/02814
(22) International Filing Date: 12 February 1998 (12.02.98)
(30) Priority Data:
08/801,741 14 February 1997 (14.02.97) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 08/801,741 (CIP)
Filed on 14 February 1997 (14.02.97)


(72) Inventors; and
(75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). GOLI, Surya, K. [IN/US]; 3311 Cantamar Court, San Jose, CA 95135 (US).


(54) Title: NOVEL HUMAN MAGO NASHI PROTEIN

```
1 MAVASDFYLRRYYGKFGHEFEFRP SEQ ID NO-1
1 MS-TEDFYLRRYYGKFGHEFEFRP GI 476103

31 DGKLRYANNSNYKNKDVMIRKEAYVHKSVME SEQ ID NO-1
30 DGKLRYANNSNYKNKDTMIRKEAFVHSQVME GI 476103

61 EKIRITDDSEITKEDDALWPMPDVRGRQEL SEQ ID NO-1
60 EKIRITDDSEITKEDDLWPMPDVRQEL GI 476103

91 EIVIGDEHISFTTSKGLIDVNSQSKDPG SEQ ID NO-1
90 EIVIGDEHISFTTSKGLIDVNRSKDPG GI 476103

121 LRVFFYYLVQDLKCLVFSLIGLHFKIKPI SEQ ID NO-1
120 LRVCFFYYLVQDLKCLVFSLIGLHFKIKPI GI 476103
```

(57) Abstract

The present invention provides a human mago nashi protein (HUMAGO) and polynucleotides which encode HUMAGO. The invention also provides genetically engineered expression vectors and host cells, and a method for producing HUMAGO. The invention also provides for agonists, antisense molecules, antibodies, or antagonists of HUMAGO, and the use thereof for the prevention and treatment of diseases associated with expression of HUMAGO. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HUMAGO.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| AA | ABB | AC | AD | AE | AF | AG | AH | AI | AL | AM | AN | AO | AP | AR | AS | AT | AU | AZ | BA | BB | BE | BF | BG | BI | BJ | BL | BM | BN | BO | BR | BS | BT | BU | BY | CA | CB | CC | CD | CF | CG | CH | CI | CM | CN | CO | CZ | DE | DK | EE | EF | EG | EH | EI | EL | EM | EN | EQ | ER | ES | ET | EU | EV | FA | FE | FG | FI | FJ | FK | FL | FM | FO | FR | FS | FT | GD | GE | GF | GG | GH | GI | GL | GM | GN | GO | GR | GS | GT | GU | GW | GX | HY | IA | ID | IE | IF | IG | IH | IL | IM | IN | IO | IY | JA | JB | JF | JG | JH | JJ | JK | JL | JM | JO | JP | JR | JM | JS | JU | KV | KW | LA | LB | LC | LD | LE | LF | LG | LH | LI | LK | LL | LM | LN | LO | LP | LR | LS | LT | LU | LV | MC | MD | MG | MK | ML | MN | MR | MS | MT | MU | MV | MW | MX | MZ | NA | NC | NE | NF | NG | NM | NO | NP | NQ | NR | NS | NT | NU | NV | NW | NX | NY | NZ | OI | OM | OR | OS | OT | OU | OV | PA | PB | PC | PD | PE | PG | PH | PI | PK | PL | PM | PN | PQ | PR | PS | PT | PU | PV | PW | PY | QT | QU | QW | QX | QY | QZ | RR | RS | RT | RU | RW | SX | SY | SZ | TB | TC | TD | TE | TF | TG | TH | TJ | TM | TN | TO | TR | TT | TW | TX | TY | TZ | UG | UA | UY | UZ | VA | VE | VF | VG | VI | VK | VL | VM | VN | VO | VR | VS | VU | VW | WX | WY | XA | XB | XY | XZ | YA | YB | YC | YD | YE | YF | YG | YH | YI | YJ | YK | YL | YM | YN | YO | YP | YQ | YR | YS | YT | YX | YY | YZ | ZA | ZB | ZC | ZD | ZE | ZF | ZG | ZH | ZI | ZJ | ZK | ZL | ZM | ZN | ZO | ZP | ZQ | ZR | ZS | ZT | ZZ | AB | AC | AD | AE | AF | AG | AH | AI | AL | AM | AN | AO | AP | AR | AS | AT | AU | AZ | BA | BB | BE | BF | BG | BI | BJ | BL | BM | BN | BO | BR | BS | BT | BU | BY | CA | CB | CC | CD | CF | CG | CH | CI | CM | CN | CO | CZ | DE | DK | EE | EF | EG | EH | EI | EL | EM | EN | EQ | ER | ES | ET | EU | EV | FA | FE | FG | FI | FJ | FK | FL | FM | FO | FR | FS | FT | GD | GE | GF | GG | GH | GI | GL | GM | GN | GO | GR | GS | GT | GU | GW | GX | HY | IA | ID | IE | IF | IG | IH | IL | IM | IN | IO | IY | JA | JB | JF | JG | JH | JJ | JK | JL | JM | JO | JP | JR | JM | JS | JU | KV | KW | LA | LB | LC | LD | LE | LF | LG | LH | LI | LK | LL | LM | LN | LO | LP | LR | LS | LT | LU | LV | MC | MD | MG | MK | ML | MN | MR | MS | MT | MU | MV | MW | MX | MZ | NA | NC | NE | NF | NG | NM | NO | NP | NQ | NR | NS | NT | NU | NV | NW | NX | NY | NZ | OI | OM | OR | OS | OT | OU | OV | PA | PB | PC | PD | PE | PG | PH | PI | PK | PL | PM | PN | PQ | PR | PS | PT | PU | PV | PW | PY | QT | QU | QW | QX | QY | QZ | RR | RS | RT | RU | RW | SX | SY | SZ | TB | TC | TD | TE | TF | TG | TH | TJ | TM | TN | TO | TR | TT | TW | TX | TY | TZ | UG | UA | UY | UZ | VA | VE | VF | VG | VI | VK | VL | VM | VN | VO | VR | VS | VU | VW | WX | WY | XA | XB | XY | XZ | YA | YB | YC | YD | YE | YF | YG | YH | YI | YJ | YK | YL | YM | YN | YO | YP | YQ | YR | YS | YT | YX | YY | YZ | ZA | ZB | ZC | ZD | ZE | ZF | ZG | ZH | ZI | ZJ | ZK | ZL | ZM | ZN | ZO | ZP | ZQ | ZR | ZS | ZT | ZZ |
NOVEL HUMAN MAGO NASHI PROTEIN

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of a novel human mago nashi protein and to the use of these sequences in the diagnosis, prevention, and treatment of cancer and developmental disorders.

BACKGROUND ART

Embryonic development in insects and vertebrates is orchestrated by the spatial and temporal regulation of a conserved set of genes (Corte, G. et al., (1993) Cancer Detect. Prev. 17: 261-266). These genes regulate important developmental functions, including cell proliferation, programmed cell death, cell migration, and differentiation. Many of these genes also function in adult organisms and some are thought to contribute to the development of human diseases, such as cancer (Blazsek, I. (1992) Biomed. Pharmacother. 46:219-235).

In the fruit fly Drosophila melanogaster, the developmental fate of a given blastomere is correlated with the region of the cytoplasm that it inherits. Experiments have shown that there are factors in the cytoplasm capable of directing developmental fates. For example, granules in the posterior pole of D. melanogaster eggs and embryos contain determinants that allow nuclei that migrate there to develop into germ cells. The microscopically observed granules, or pole plasm, are composed of protein and RNA and appear in many organisms, such as worms and amphibia. Through experiments in which cytoplasm from the posterior pole of D. melanogaster embryos was removed, Frohnhöfer H.G. et al. (1986, J. Embryol. Exp. Morph. 97 Suppl.:169-179) found that the granules also contribute to the developmental process of abdominal segmentation.

Genetic mutations have been discovered which mimic the segmentation and germ cell defects of granule removal. In fact, females carrying some of these mutations, known as posterior group maternal effect mutations, produce embryos which lack granules. Mago nashi (means “grandchildless”, in Japanese) is such a mutation (Boswell R. E. et al. (1991) Development 113: 373-384).

D. melanogaster mago nashi is a 147 amino acid protein that lacks homology to known proteins. The carboxy terminus of the protein is slightly hydrophobic and could serve as a transmembrane domain. Mutations in mago nashi disrupt the polar localization of the germ plasm components, oskar mRNA and staufen protein (Newmark P.A. et al. (1994) Development 120:1303-1313). Mago nashi mRNA is expressed throughout the fly life cycle and occurs with similar abundance in larvae, adult males, and adult females. Expression of mago nashi in
developmental stages beyond embryogenesis and analysis of particular mago nashi mutants suggests that the gene product serves important functions in adult flies. In addition, expressed sequence tags from several species encode protein fragments that show homology to D. melanogaster mago nashi. Therefore, mago nashi is conserved over large evolutionary distances and is likely to serve important functions in many species (Newmark et al., supra).

Discovery of proteins related to D. melanogaster mago nashi and the polynucleotides encoding them satisfies a need in the art by providing new compositions useful in diagnosis, prevention, and treatment of cancer and developmental disorders.

DISCLOSURE OF THE INVENTION

The present invention features a novel human mago nashi protein hereinafter designated HUMAGO and characterized as having similarity to D. melanogaster mago nashi protein.

Accordingly, the invention features a substantially purified HUMAGO having the amino acid sequence shown in SEQ ID NO:1.

One aspect of the invention features isolated and substantially purified polynucleotides that encode HUMAGO. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2.

The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2 or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2.

The invention additionally features nucleic acid sequences encoding polypeptides, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode HUMAGO. The present invention also features antibodies which bind specifically to HUMAGO, and pharmaceutical compositions comprising substantially purified HUMAGO. The invention also features agonists and antagonists of HUMAGO. The invention also features a method for producing HUMAGO, and methods for treating developmental disorders by administering HUMAGO or an agonist to HUMAGO. In addition, the invention features methods for treating cancer by administering an antagonist to HUMAGO.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A and 1B shows the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of HUMAGO. The alignment was produced using MacDNAISIS PRO™ software (Hitachi Software Engineering Co., Ltd., San Bruno, CA).

Figure 2 shows the amino acid sequence alignments between HUMAGO (SEQ ID NO:1)
and *D. melanogaster* mago nashi (GI 476103; SEQ ID NO:3). The alignment was produced using
the multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

Figure 3 shows the hydrophobicity plot (MacDNASIS PRO software) for HUMAGO,
SEQ ID NO: 1; the positive X axis reflects amino acid position, and the negative Y axis,
hydrophobicity.

Figure 4 shows the hydrophobicity plot for *D. melanogaster* mago nashi, SEQ ID NO:3.

**MODES FOR CARRYING OUT THE INVENTION**

Before the present proteins, nucleotide sequences, and methods are described, it is
understood that this invention is not limited to the particular methodology, protocols, cell lines,
vectors, and reagents described as these may vary. It is also to be understood that the terminology
used herein is for the purpose of describing particular embodiments only, and is not intended to
limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms “a”,
“an”, and “the” include plural reference unless the context clearly dictates otherwise. Thus, for
example, reference to “a host cell” includes a plurality of such host cells, reference to the
“antibody” is a reference to one or more antibodies and equivalents thereof known to those
skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same
meanings as commonly understood by one of ordinary skill in the art to which this invention
belongs. Although any methods and materials similar or equivalent to those described herein can
be used in the practice or testing of the present invention, the preferred methods, devices, and
materials are now described. All publications mentioned herein are incorporated herein by
reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies
which are reported in the publications which might be used in connection with the invention.

Nothing herein is to be construed as an admission that the invention is not entitled to antedate
such disclosure by virtue of prior invention.

**DEFINITIONS**

“Nucleic acid sequence” as used herein refers to an oligonucleotide, nucleotide, or
polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic
origin which may be single- or double-stranded, and represent the sense or antisense strand.
Similarly, “peptide sequence” as used herein refers to an oligopeptide, peptide, polypeptide,
or protein sequence, and fragments or portions thereof, and to naturally occurring or synthetic
molecules.
Where “amino acid sequence” is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms, such as “polypeptide” or “protein” are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

“Peptide nucleic acid”, as used herein, refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary strand of nucleic acid (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

HUMAGO, as used herein, refers to the amino acid sequences of substantially purified HUMAGO obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

“Consensus”, as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, or which has been extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5’ and/or the 3’ direction and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte clone using the GELVIEW™ Fragment Assembly system (GCG, Madison, WI), or which has been both extended and assembled.

A “variant” of HUMAGO, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have “conservative” changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have “nonconservative” changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

A “deletion”, as used herein, refers to a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent.

An “insertion” or “addition”, as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the naturally occurring molecule.

A “substitution”, as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.
The term “biologically active”, as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, “immunologically active” refers to the capability of the natural, recombinant, or synthetic HUMAGO, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term “agonist”, as used herein, refers to a molecule which, when bound to HUMAGO, causes a change in HUMAGO which modulates the activity of HUMAGO. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to HUMAGO.

The terms “antagonist” or “inhibitor”, as used herein, refer to a molecule which, when bound to HUMAGO, blocks or modulates the biological or immunological activity of HUMAGO. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to HUMAGO.

The term “modulate”, as used herein, refers to a change or an alteration in the biological activity of HUMAGO. Modulation may be an increase or a decrease in protein activity, a change in binding characteristics, or any other change in the biological, functional or immunological properties of HUMAGO.

The term “mimetic”, as used herein, refers to a molecule, the structure of which is developed from knowledge of the structure of HUMAGO or portions thereof and, as such, is able to effect some or all of the actions of mago nashi protein-like molecules.

The term “derivative”, as used herein, refers to the chemical modification of a nucleic acid encoding HUMAGO or the encoded HUMAGO. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a polypeptide which retains essential biological characteristics of the natural molecule.

The term “substantially purified”, as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

“Amplification” as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

The term “hybridization”, as used herein, refers to any process by which a strand of
nucleic acid binds with a complementary strand through base pairing.

The term “hybridization complex”, as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., Cₐt or Rₐt analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., membranes, filters, chips, pins or glass slides to which cells have been fixed for in situ hybridization).

The terms “complementary” or “complementarity”, as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, for the sequence “A-G-T” binds to the complementary sequence “T-C-A”.

Complementarity between two single-stranded molecules may be “partial”, in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands.

The term “homology”, as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence is one that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid; it is referred to using the functional term “substantially homologous.” The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence or probe to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.
As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about Tm-5°C (5°C below the melting temperature (Tm) of the probe) to about 20°C to 25°C below Tm. As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

The term “antisense”, as used herein, refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term “antisense strand” is used in reference to a nucleic acid strand that is complementary to the “sense” strand. Antisense molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a complementary strand. Once introduced into a cell, this transcribed strand combines with natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription or translation. In this manner, mutant phenotypes may be generated. The designation “negative” is sometimes used in reference to the antisense strand, and “positive” is sometimes used in reference to the sense strand.

The term “portion”, as used herein, with regard to a protein (as in “a portion of a given protein”) refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein “comprising at least a portion of the amino acid sequence of SEQ ID NO:1” encompasses the full-length human HUMAGO and fragments thereof.

“Transformation”, as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, viral infection, electroporation, lipofection, and particle bombardment. Such “transformed” cells
include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

The term "antigenic determinant", as used herein, refers to that portion of a molecule that makes contact with a particular antibody (i.e., an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The terms "specific binding" or "specifically binding", as used herein, in reference to the interaction of an antibody and a protein or peptide, mean that the interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) on the protein; in other words, the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding HUMAGO or fragments thereof may comprise a cell, chromosomes isolated from a cell (e.g., a spread of metaphase chromosomes), genomic DNA (in solution or bound to a solid support such as for Southern analysis), RNA (in solution or bound to a solid support such as for northern analysis), cDNA (in solution or bound to a solid support), an extract from cells or a tissue, and the like.

The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2 by northern analysis is indicative of the presence of mRNA encoding HUMAGO in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

"Alterations" in the polynucleotide of SEQ ID NO: 2, as used herein, comprise any alteration in the sequence of polynucleotides encoding HUMAGO including deletions, insertions, and point mutations that may be detected using hybridization assays. Included within this definition is the detection of alterations to the genomic DNA sequence which encodes HUMAGO (e.g., by alterations in the pattern of restriction fragment length polymorphisms capable of hybridizing to SEQ ID NO:2), the inability of a selected fragment of SEQ ID NO: 2 to hybridize
to a sample of genomic DNA (e.g., using allele-specific oligonucleotide probes), and improper or unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HUMAGO (e.g., using fluorescent in situ hybridization [FISH] to metaphase chromosomes spreads).

As used herein, the term “antibody” refers to intact molecules as well as fragments thereof, such as F(ab′)₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind HUMAGO polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal can be derived from the transition of RNA or synthesized chemically, and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

The term “humanized antibody”, as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

**THE INVENTION**

The invention is based on the discovery of a novel human mago nashi protein, (HUMAGO), the polynucleotides encoding HUMAGO, and the use of these compositions for the diagnosis, prevention, or treatment of cancer and developmental disorders.

Nucleic acids encoding the human HUMAGO of the present invention were first identified in Incyte Clone 2278920 from the normalized prostate tissue cDNA library (PROSNON01) through a computer-generated search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 2278920, 1492969 (PROSNON01), and 53661 (FIBRNOT01).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figures 1A and 1B. HUMAGO is 148 amino acids in length and has a conserved potential N-glycosylation site at asparagine residue 113. HUMAGO has chemical and structural homology with D. melanogaster mago nashi (GI 476103; SEQ ID NO:3). In particular, HUMAGO and D. melanogaster mago nashi share 90% identity. As illustrated by Figures 3 and 4, HUMAGO and D. melanogaster mago nashi have rather similar hydrophobicity plots. Both proteins contain a potential transmembrane domain at their carboxy terminus. Northern analysis shows the expression of HUMAGO in various libraries, a high
proportion of which are from fetal tissues and cancerous cells.

The invention also encompasses HUMAGO variants. A preferred HUMAGO variant is one having at least 80%, and more preferably 90%, amino acid sequence identity to the HUMAGO amino acid sequence (SEQ ID NO:1). A most preferred HUMAGO variant is one having at least 95% amino acid sequence identity to SEQ ID NO:1.

The invention also encompasses polynucleotides which encode HUMAGO. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of HUMAGO can be used to generate recombinant molecules which express HUMAGO. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid sequence of SEQ ID NO:2 as shown in Figures 1A and 1B.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding HUMAGO, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring HUMAGO, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode HUMAGO and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring HUMAGO under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HUMAGO or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HUMAGO and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or portions thereof, which encode HUMAGO and its derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding
HUMAGO or any portion thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, under various conditions of stringency. Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe, as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511), and may be used at a defined stringency.

Altered nucleic acid sequences encoding HUMAGO which are encompassed by the invention include deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent HUMAGO. The encoded protein may also contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HUMAGO. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of HUMAGO is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.

Also included within the scope of the present invention are alleles of the genes encoding HUMAGO. As used herein, an “allele” or “allelic sequence” is an alternative form of the gene which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

Methods for DNA sequencing which are well known and generally available in the art may be used to practice any embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp. Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg, MD).
Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI 377 DNA sequencers (Perkin Elmer).

The nucleic acid sequences encoding HUMAGO may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers may be designed using OLIIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene.

The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk in genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed
library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into the 5' and 3' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence Navigator™, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HUMAGO, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of HUMAGO in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express HUMAGO.

As will be understood by those of skill in the art, it may be advantageous to produce HUMAGO-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter HUMAGO encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.
In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding HUMAGO may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of HUMAGO activity, it may be useful to encode a chimeric HUMAGO protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the HUMAGO encoding sequence and the heterologous protein sequence, so that HUMAGO may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding HUMAGO may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of HUMAGO, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of HUMAGO, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active HUMAGO, the nucleotide sequences encoding HUMAGO or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding HUMAGO and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.
A variety of expression vector/host systems may be utilized to contain and express sequences encoding HUMAGO. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

The “control elements” or “regulatory sequences” are those non-translated regions of the vector—enhancers, promoters, 5' and 3' untranslated regions—which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding HUMAGO, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for HUMAGO. For example, when large quantities of HUMAGO are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding HUMAGO may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made
in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, seeAusubel et al. (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding HUMAGO may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.

An insect system may also be used to express HUMAGO. For example, in one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequences encoding HUMAGO may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of HUMAGO will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda* cells or *Trichoplusia* larvae in which HUMAGO may be expressed (Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding HUMAGO may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing HUMAGO in infected host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.
Specific initiation signals may also be used to achieve more efficient translation of sequences encoding HUMAGO. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding HUMAGO, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express HUMAGO may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk' or aprt' cells, respectively. Also, antimetabolite,
antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which
npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F.
et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and
phosphonitricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have
been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or
hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan
popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and
luciferase and its substrate luciferin, being widely used not only to identify transformants, but
also to quantify the amount of transient or stable protein expression attributable to a specific

Although the presence/absence of marker gene expression suggests that the gene of
interest is also present, its presence and expression may need to be confirmed. For example, if
the sequence encoding HUMAGO is inserted within a marker gene sequence, recombinant cells
containing sequences encoding HUMAGO can be identified by the absence of marker gene
function. Alternatively, a marker gene can be placed in tandem with a sequence encoding
HUMAGO under the control of a single promoter. Expression of the marker gene in response to
induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding HUMAGO and
express HUMAGO may be identified by a variety of procedures known to those of skill in the art.
These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and
protein bioassay or immunoassay techniques which include membrane, solution, or chip based
technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding HUMAGO can be detected by
DNA-DNA or DNA-RNA hybridization or amplification using probes or portions or fragments of
polynucleotides encoding HUMAGO. Nucleic acid amplification based assays involve the use of
oligonucleotides or oligomers based on the sequences encoding HUMAGO to detect
transformants containing DNA or RNA encoding HUMAGO. As used herein “oligonucleotides”
or “oligomers” refer to a nucleic acid sequence of at least about 10 nucleotides and as many as
about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25
nucleotides, which can be used as a probe or amplimer.

A variety of protocols for detecting and measuring the expression of HUMAGO, using
either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HUMAGO is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983; J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HUMAGO include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding HUMAGO, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH). Suitable reporter molecules or labels, which may be used, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding HUMAGO may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HUMAGO may be designed to contain signal sequences which direct secretion of HUMAGO through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding HUMAGO to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or
enterokinase (Invitrogen, San Diego, CA) between the purification domain and HUMAGO may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing HUMAGO and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3: 263-281) while the enterokinase cleavage site provides a means for purifying HUMAGO from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

In addition to recombinant production, fragments of HUMAGO may be produced by direct peptide synthesis using solid-phase techniques Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of HUMAGO may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

15 THERAPEUTICS

Based on the chemical and structural homology between HUMAGO and D. melanogaster mago nashi, and the expression of HUMAGO in fetal and cancerous tissues, HUMAGO appears to be associated with cancer and developmental diseases.

Like the D. melanogaster mago nashi protein, HUMAGO may stimulate important developmental changes, such as the organization of a body plan and the maturation of germ cells. Therefore, in one embodiment, HUMAGO or a fragment or derivative thereof may be administered to a subject to treat developmental disorders, including but not limited to, incomplete organ development, mental retardation, infertility, spina bifida, immunologic deficiency diseases, dwarfism, neural tube defects, arthrogryposis multiplex congenita, and musculoskeletal defects.

In another embodiment, agonists of HUMAGO may also be administered to a subject to treat the developmental disorders described above.

In another embodiment, a vector capable of expressing HUMAGO, or a fragment or a derivative thereof, may also be administered to a subject to treat the developmental disorders described above.

Antagonists or inhibitors of HUMAGO may be used to suppress excessive cell proliferation. In one embodiment, antagonists or inhibitors of HUMAGO may be administered to a subject to treat or prevent cancer, including but not limited to, cancers of the prostate, testes,
penis, paraganglion, lung, pancreas, and brain.

In one aspect, antibodies which are specific for HUMAGO may be used directly as an antagonist, or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express HUMAGO.

In another embodiment, a vector expressing antisense of the polynucleotide encoding HUMAGO may be administered to a subject to treat or prevent cancer, including but not limited to, the cancers listed above.

In other embodiments, any of the therapeutic proteins, antagonists, antibodies, agonists, antisense sequences or vectors described above may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Antagonists or inhibitors of HUMAGO may be produced using methods which are generally known in the art. In particular, purified HUMAGO may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind HUMAGO.

The antibodies may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with HUMAGO or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guérin) and Corynebacterium parvum are especially preferable.

It is preferred that the peptides, fragments, or oligopeptides used to induce antibodies to HUMAGO have an amino acid sequence consisting of at least five amino acids, and more
preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HUMAGO amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.


Antibody fragments which contain specific binding sites for HUMAGO may also be generated. For example, such fragments include, but are not limited to, the F(ab')2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al. (1989) Science 254:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in
the art. Such immunoassays typically involve the measurement of complex formation between HUMAGO and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HUMAGO epitopes is preferred, but a competitive binding assay may also be employed (Maddox, supra).

In another embodiment of the invention, the polynucleotides encoding HUMAGO, or any fragment thereof, or antisense molecules, may be used for therapeutic purposes. In one aspect, antisense to the polynucleotide encoding HUMAGO may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HUMAGO. Thus, antisense molecules may be used to modulate HUMAGO activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding HUMAGO.

Expression vectors derived from retro viruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense molecules complementary to the polynucleotides of the gene encoding HUMAGO. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).

Genes encoding HUMAGO can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes HUMAGO. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases.

Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA, or PNA, to the control regions of the gene encoding HUMAGO, i.e., the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic
advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding

HUMAGO.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by \textit{in vitro} and \textit{in vivo} transcription of DNA sequences encoding HUMAGO. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2'-O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queoseine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.
Many methods for introducing vectors into cells or tissues are available and equally suitable for use in *vivo*, in *vitro*, and *ex vivo*. For *ex vivo* therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HUMAGO, antibodies to HUMAGO, mimetics, agonists, antagonists, or inhibitors of HUMAGO. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of *Remington's Pharmaceutical Sciences* (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active
compounds with solid excipient, optionally grinding a resulting mixture, and processing the
mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose,
mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as
methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums
including arabic and tragacanth; and proteins such as gelatin and collagen. If desired,
disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl
pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated
sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel,
polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or
solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for
product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of
gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.
Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or
starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft
capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty
oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in
aqueous solutions, preferably in physiologically compatible buffers such as Hanks’s solution,
Ringer’s solution, or physiologically buffered saline. Aqueous injection suspensions may contain
substances which increase the viscosity of the suspension, such as sodium carboxymethyl
cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be
prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles
include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or
agents which increase the solubility of the compounds to allow for the preparation of highly
concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be
permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a
manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating.
dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of HUMAGO, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example HUMAGO or fragments thereof, antibodies of HUMAGO, agonists, antagonists or inhibitors of HUMAGO, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient
levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.

Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

**DIAGNOSTICS**

In another embodiment, antibodies which specifically bind HUMAGO may be used for the diagnosis of conditions or diseases characterized by expression of HUMAGO, or in assays to monitor patients being treated with HUMAGO, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for HUMAGO include methods which utilize the antibody and a label to detect HUMAGO in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring HUMAGO are known in the art and provide a basis for diagnosing altered or abnormal levels of HUMAGO expression. Normal or standard values for HUMAGO expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to HUMAGO under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric, means. Quantities of HUMAGO expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding HUMAGO may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide
sequences, antisense RNA and DNA molecules, and PNA's. The polynucleotides may be used to
detect and quantitate gene expression in biopsied tissues in which expression of HUMAGO may
be correlated with disease. The diagnostic assay may be used to distinguish between absence,
presence, and excess expression of HUMAGO, and to monitor regulation of HUMAGO levels
during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting
polynucleotide sequences, including genomic sequences, encoding HUMAGO or closely related
molecules, may be used to identify nucleic acid sequences which encode HUMAGO. The
specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique
nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding
region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or
low) will determine whether the probe identifies only naturally occurring sequences encoding
HUMAGO, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably
contain at least 50% of the nucleotides from any of the HUMAGO encoding sequences. The
hybridization probes of the subject invention may be DNA or RNA and derived from the
nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer
elements, and introns of the naturally occurring HUMAGO.

Means for producing specific hybridization probes for DNAs encoding HUMAGO
include the cloning of nucleic acid sequences encoding HUMAGO or HUMAGO derivatives into
vectors for the production of mRNA probes. Such vectors are known in the art, commercially
available, and may be used to synthesize RNA probes in vitro by means of the addition of the
appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may
be labeled by a variety of reporter groups, for example, radionuclides such as 32P or 35S, or
enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling
systems, and the like.

Polynucleotide sequences encoding HUMAGO may be used for the diagnosis of
conditions or diseases which are associated with expression of HUMAGO. Examples of such
conditions or diseases include cancers of the prostate, testes, penis, paraganglion, lung, pancreas,
and brain. The polynucleotide sequences encoding HUMAGO may be used in Southern or
northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dip
stick, pIN, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered
HUMAGO expression. Such qualitative or quantitative methods are well known in the art.
In a particular aspect, the nucleotide sequences encoding HUMAGO may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequences encoding HUMAGO may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding HUMAGO in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of HUMAGO, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes HUMAGO, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding
HUMAGO may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'->3') and another with antisense (3'<-5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HUMAGO include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In another embodiment of the invention, the nucleic acid sequences which encode HUMAGO may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include FISH, FACS, or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) Blood Rev. 7:127-134, and Trask, B.J. (1991) Trends Genet. 7:149-154.

FISH (as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of Science (265:1981f). Correlation between the location of the gene encoding HUMAGO on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as
mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, HUMAGO, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between HUMAGO and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to HUMAGO large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with HUMAGO, or fragments thereof, and washed. Bound HUMAGO is then detected by methods well known in the art. Purified HUMAGO can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HUMAGO specifically compete with a test compound for binding HUMAGO. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HUMAGO.

In additional embodiments, the nucleotide sequences which encode HUMAGO may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included.
for the purpose of limiting the invention.

INDUSTRIAL APPLICABILITY

I  PROSNON01 cDNA Library Construction

The PROSNON01 normalized cDNA library was constructed from microscopically
5 normal prostate tissue obtained from a 28-year-old Caucasian male (specimen RA95-09-0667;
International Institute for the Advancement of Medicine, Exton, PA) who died from a self
inflicted gun shot wound. Patient history included alcohol and tobacco use.

The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron
PT-3000 (Brinkmann Instruments, Westbury, NY) in guanidinium isothiocyanate solution. The
lysate was centrifuged over a 5.7 M CsCl cushion using an Beckman SW28 rotor in a Beckman
L8-70M Ultracentrifuge (Beckman Instruments) for 18 hours at 25,000 rpm at ambient
temperature. The RNA was extracted with acid phenol pH 4.7, precipitated using 0.3 M sodium
acetate and 2.5 volumes of ethanol, resuspended in RNAse-free water, and DNase treated at
37°C. Extraction and precipitation were repeated as before. The mRNA was isolated with the
15 Qiagen Oligotex kit (QIAGEN, Inc., Chatsworth, CA) and used to construct the cDNA library.

The RNA was handled according to the recommended protocols in the SuperScript
Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat. #18248-013; Gibco/BRL,
Gaithersberg, MD). The cDNAs were fractionated on a Sepharose CL4B column (Catalog
#275105-01, Pharmacia), and those cDNAs exceeding 400 bp were ligated into pSport 1. The
20 plasmid pSport 1 was subsequently transformed into DH5a™ competent cells (Catalog #18258-
012, Gibco/BRL).

II. Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid
Kit (Catalog #26173, QIAGEN, Inc.). This kit enabled the simultaneous purification of 96
25 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol
was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile
Terrific Broth (Catalog #22711, LIFE TECHNOLOGIES™, Gaithersburg, MD) with
carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for
19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3)
30 following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of
distilled water. After the last step in the protocol, samples were transferred to a 96-well block for
storage at 4° C.

The cDNAs were sequenced by the method of Sanger et al. (1975, J. Mol. Biol. 94:441f),
-33-
using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied Biosystems 377 DNA Sequencing Systems; and the reading frame was determined.

III. Homology Searching of cDNA Clones and Their Deduced Proteins

The nucleotide sequences of the Sequence Listing or amino acid sequences deduced from them were used as query sequences against databases such as GenBank, SwissProt, BLOCKS, and Pima II. These databases which contain previously identified and annotated sequences were searched for regions of homology (similarity) using BLAST, which stands for Basic Local Alignment Search Tool (Altschul (1993) supra, Altschul (1990) supra).

BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal or plant) origin. Other algorithms such as the one described in Smith et al. (1992 Protein Engineering 5:35-51), incorporated herein by reference, can be used when dealing with primary sequence patterns and secondary structure gap penalties. As disclosed in this application, the sequences have lengths of at least 49 nucleotides, and no more than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

The BLAST approach, as detailed in Karlin and Altschul (supra) and incorporated herein by reference, searches for matches between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. In this application, threshold was set at $10^{-25}$ for nucleotides and $10^{-14}$ for peptides.

Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and mammalian sequences (mam), and deduced amino acid sequences from the same clones are searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp) and eukaryote (eukp), for homology. The relevant database for a particular match were reported as a G1xxx+p (where xxx is pri, rod, etc. and, if present, p = peptide). The product score is calculated as follows: the % nucleotide or amino acid identity [between the query and reference sequences] in BLAST is multiplied by the % maximum possible BLAST score [based on the lengths of query and reference sequences] and then divided by 100. Where an Incyte Clone was homologous to several sequences, up to five matches were provided with their relevant scores. In an analogy to the hybridization procedures used in the laboratory, the electronic stringency for an exact match was set at 70, and the conservative lower limit for an
exact match was set at approximately 40 (with 1-2% error due to uncalled bases).

IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., supra).

Analogous computer techniques using BLAST (Altschul, S.F. 1993 and 1990, supra) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFSEQU™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

\[
\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}
\]

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding HUMAGO occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

V Extension of HUMAGO-Encoding Polynucleotides to Full Length or to Recover

Regulatory Sequences

Full length HUMAGO-encoding nucleic acid sequence (SEQ ID NO:2) is used to design oligonucleotide primers for extending a partial nucleotide sequence to full length or for obtaining 5' or 3', intron or other control sequences from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers are used to facilitate the extension of the known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers are designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC
content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. 
Any stretch of nucleotides which would result in hairpin structures and primer-primer 
dimerizations is avoided.

The original, selected cDNA libraries, or a human genomic library are used to extend the 
sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary 
or desired, additional sets of primers are designed to further extend the known region.

By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing 
the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of 
each primer and the recommended concentrations of all other components of the kit, PCR is 
performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the 
following parameters:

<table>
<thead>
<tr>
<th>Step</th>
<th>Temperature</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>94°C</td>
<td>1 min</td>
</tr>
<tr>
<td>2</td>
<td>65°C</td>
<td>1 min</td>
</tr>
<tr>
<td>3</td>
<td>68°C</td>
<td>6 min</td>
</tr>
<tr>
<td>4</td>
<td>94°C</td>
<td>15 sec</td>
</tr>
<tr>
<td>5</td>
<td>65°C</td>
<td>1 min</td>
</tr>
<tr>
<td>6</td>
<td>68°C</td>
<td>7 min</td>
</tr>
<tr>
<td>7</td>
<td>Repeat step 4-6 for 15 additional cycles</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>94°C</td>
<td>15 sec</td>
</tr>
<tr>
<td>9</td>
<td>65°C</td>
<td>1 min</td>
</tr>
<tr>
<td>10</td>
<td>68°C</td>
<td>7:15 min</td>
</tr>
<tr>
<td>11</td>
<td>Repeat step 8-10 for 12 cycles</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>72°C</td>
<td>8 min</td>
</tr>
<tr>
<td>13</td>
<td>4°C</td>
<td>(and holding)</td>
</tr>
</tbody>
</table>

A 5-10 μl aliquot of the reaction mixture is analyzed by electrophoresis on a low 
concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in 
extending the sequence. Bands thought to contain the largest products are selected and removed 
from the gel. Further purification involves using a commercial gel extraction method such as 
QIAQuick™ (QIAGEN Inc., Chatsworth, CA). After recovery of the DNA, Klenow enzyme is 
used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation 
and cloning.

After ethanol precipitation, the products are redisolved in 13 μl of ligation buffer, 1μl 
T4-DNA ligase (15 units) and 1μl T4 polynucleotide kinase are added, and the mixture is 
incubated at room temperature for 2-3 hours or overnight at 16° C. Competent E. coli cells (in 
40 μl of appropriate media) are transformed with 3 μl of ligation mixture and cultured in 80 μl of 
SOC medium (Sambrook et al., supra). After incubation for one hour at 37° C, the whole
transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook et al., supra) containing 2x Carb. The following day, several colonies are randomly picked from each plate and cultured in 150 µl of liquid LB/2x Carb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 µl of each

overnight culture is transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 µl of each sample is transferred into a PCR array.

For PCR amplification, 18 µl of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction are added to each well. Amplification is performed using the following conditions:

<table>
<thead>
<tr>
<th>Step</th>
<th>Temperature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1</td>
<td>94°C for 60 sec</td>
</tr>
<tr>
<td>Step 2</td>
<td>94°C for 20 sec</td>
</tr>
<tr>
<td>Step 3</td>
<td>55°C for 30 sec</td>
</tr>
<tr>
<td>Step 4</td>
<td>72°C for 90 sec</td>
</tr>
<tr>
<td>Step 5</td>
<td>Repeat steps 2-4 for an additional 29 cycles</td>
</tr>
<tr>
<td>Step 6</td>
<td>72°C for 180 sec</td>
</tr>
<tr>
<td>Step 7</td>
<td>4°C (and holding)</td>
</tr>
</tbody>
</table>

Aliquots of the PCR reactions are run on agarose gels together with molecular weight markers. The sizes of the PCR products are compared to the original partial cDNAs, and appropriate clones are selected, ligated into plasmid, and sequenced.

VI Labeling and Use of Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 µCi of [γ-32P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont NEN®, Boston, MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A portion containing 10⁷ counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba 1, or Pvu II; DuPont NEN®).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room
temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester, NY) is exposed to the blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

5 VII Antisense Molecules

Antisense molecules to the HUMAGO-encoding sequence, or any part thereof, is used to inhibit in vivo or in vitro expression of naturally occurring HUMAGO. Although use of antisense oligonucleotides, comprising about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide based on the coding sequences of HUMAGO, as shown in Figures 1A and 1B, is used to inhibit expression of naturally occurring HUMAGO. The complementary oligonucleotide is designed from the most unique 5' sequence as shown in Figures 1A and 1B and used either to inhibit transcription by preventing promoter binding to the upstream nontranslated sequence or translation of an HUMAGO-encoding transcript by preventing the ribosome from binding. Using an appropriate portion of the signal and 5' sequence of SEQ ID NO:2, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or 5' coding sequence of the polypeptide as shown in Figures 1A and 1B.

VIII Expression of HUMAGO

Expression of HUMAGO is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector, pSport, previously used for the generation of the cDNA library is used to express HUMAGO in E. coli. Upstream of the cloning site, this vector contains a promoter for β-galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β-galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of β-galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of HUMAGO into the bacterial growth media which can be used directly in the following assay for activity.

IX Demonstration of HUMAGO Activity

HUMAGO can at least partially complement mutations in D. melanogaster mago nashi by a P element-mediated transformation technique described by Newmark et al. (supra). The
The coding sequence of HUMAGO is fused to the promoter region of the D. melanogaster mago nashi gene and the construct cloned into the transformation vector pCaSpeR 4. The construct is then co-injected with pπ25.7wc helper plasmid into Df(l)w, yw,67c23 embryos. The insertions are then mobilized using Δ2-3 as a genomic source of transposase and flies bearing insertions on the X chromosome are obtained. The development and/or fertility of offspring demonstrates complementation of a mutation in the D. melanogaster mago nashi gene.

X Production of HUMAGO Specific Antibodies

HUMAGO that is substantially purified using PAGE electrophoresis (Sambrook, supra), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2 is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopolypeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (supra), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmochemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

XI Purification of Naturally Occurring HUMAGO Using Specific Antibodies

Naturally occurring or recombinant HUMAGO is substantially purified by immunoaffinity chromatography using antibodies specific for HUMAGO. An immunoaffinity column is constructed by covalently coupling HUMAGO antibody to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HUMAGO is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HUMAGO (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HUMAGO binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and HUMAGO is collected.
Identification of Molecules Which Interact with HUMAGO

HUMAGO or biologically active fragments thereof are labeled with $^{125}\text{I}$ Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HUMAGO, washed and any wells with labeled HUMAGO complex are assayed. Data obtained using different concentrations of HUMAGO are used to calculate values for the number, affinity, and association of HUMAGO with the candidate molecules.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.
SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: INCYTE PHARMACEUTICALS, INC.

(ii) TITLE OF THE INVENTION: NOVEL HUMAN MAGO NASHI PROTEIN

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
(B) STREET: 3174 Porter Drive
(C) CITY: Palo Alto
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 94304

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:
(A) PCT APPLICATION NUMBER: To Be Assigned
(B) FILING DATE: Filed Herewith
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Billings, Lucy J.
(B) REGISTRATION NUMBER: 36,749
(C) REFERENCE/DOCKET NUMBER: PF-0212 PCT

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 650-855-0555
(B) TELEFAX: 650-845-4166

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 148 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
Met Ala Val Ala Ser Asp Phe Tyr Leu Arg Tyr Tyr Val Gly His Lys
1   5  10  15
Gly Lys Phe Gly His Glu Phe Leu Glu Phe Glu Phe Arg Pro Asp Gly
20  25  30
Lys Leu Arg Tyr Ala Asn Asn Ser Tyr Lys Asn Asp Val Met Ile
35  40  45
Arg Lys Glu Ala Tyr Val His Lys Ser Val Met Glu Glu Leu Lys Arg
50  55  60
Ile Ile Asp Asp Ser Glu Ile Thr Lys Glu Asp Ala Leu Trp Pro
65  70  75  80
Pro Pro Asp Arg Val Gly Arg Gln Glu Leu Glu Ile Val Ile Gly Asp
85  90  95
Glu His Ile Ser Phe Thr Thr Ser Lys Ile Gly Ser Leu Ile Asp Val
100 105 110
```
Asn Gln Ser Lys Asp Pro Glu Gly Leu Arg Val Phe Tyr Tyr Leu Val 115 120 125
Gln Asp Leu Lys Cys Leu Val Phe Ser Leu Ile Gly Leu His Phe Lys 130 135 140
Ile Lys Pro Ile 145

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 514 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(x) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
GTCACTGCAA GGCCCGCGGG GACACGTTGC TTGCCTTTTC GCCTGGCTTC GCCTTGCTTC GGCGGGCTTC CCGGCTGACAA 60
AAATGGCTGG G CCTTACCGAT TCTTACCTGC GCTACTACGT AGGGCCACAAG GCACAGTGGTG 120
GCGCCGGAGGT TCTGGACTTC GAAATCTGGGC CGACCGGAAA ACTTACTATGTC GACAGCAACA 180
GCATTACAA AAATGAAATGG TAGATAGAAG CACACAGCAGA AAGAGCTTCA TTGACAGCTTCT 240
AAGAAGCAGGA GAAATCTTTT GATGAAGATGT AAATACATATGG ATTTACATATGG ATACACATAT 300
CTTGCAGTTA CAGTGGTGGTC CGCCAGGACG TTAGATATGTC AATGGAGATGT GACAGCAACA 360
CTTACCAACTTTCATCAAAAA AATCTCCTGAA TGTATGTTAAA TCACGACCAAG GACCTGGAAG 420
GCTTGCAGGT ATTTACATAT TTGGTACAAG ACTTGGAATG TTTAATTTCTC TTTTATTTTG 480
GATTACACTT CAAGATTTAAAA CCAATTTAAA TTTGT 514
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 147 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(A) LIBRARY: GenBank
(B) CLONE: 476103

(x) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
Met Ser Thr Glu Asp Phe Tyr Leu Arg Tyr Tyr Val Gly His Lys Gly 1 5 10 15
Lys Phe Gly His Glu Phe Leu Glu Phe Glu Phe Arg Pro Asp Gly Lys 20 25 30
Leu Arg Tyr Ala Asn Asn Ser Asn Tyr Lys Asn Asp Thr Met Ile Arg 35 40 45
Lys Glu Ala Phe Val His Gln Ser Val Met Glu Leu Lys Arg Ile 50 55 60
Ile Ile Asp Ser Glu Ile Met Gln Glu Asp Leu Pro Trp Pro Pro 65 70 75 80
Pro Asp Arg Val Gly Arg Gln Glu Leu Glu Ile Val Ile Gly Asp Glu 85 90 95
His Ile Ser Phe Thr Thr Ser Lys Thr Gly Ser Leu Val Asp Val Asn 100 105 110
Arg Ser Lys Asp Pro Glu Gly Leu Arg Cys Phe Tyr Tyr Leu Val Gln 115 120 125
Asp Leu Lys Cys Leu Val Phe Ser Leu Ile Gly Leu His Phe Lys Ile 130 135 140
Lys Pro Ile 145
```
What is claimed is:

1. A substantially purified human mago nashi protein comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.
2. An isolated and purified polynucleotide sequence encoding the human mago nashi protein of claim 1.
3. A polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 2.
4. A hybridization probe comprising the polynucleotide sequence of claim 2.
5. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or variants thereof.
6. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 2 or variants thereof.
7. A hybridization probe comprising the polynucleotide sequence of claim 6.
8. An expression vector containing the polynucleotide sequence of claim 2.
9. A host cell containing the vector of claim 8.
10. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 the method comprising the steps of:
   a) culturing the host cell of claim 9 under conditions suitable for the expression of the polypeptide; and
   b) recovering the polypeptide from the host cell culture.
11. A pharmaceutical composition comprising a substantially purified human mago nashi protein having an amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.
12. A purified antibody which binds specifically to the polypeptide of claim 1.
13. A purified agonist which specifically binds to and modulates the activity of the polypeptide of claim 1.
14. A purified antagonist which modulates the activity of the polypeptide of claim 1.
15. A method for treating a developmental disorder comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 11.
16. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 14.
17. A method for detection of a polynucleotide which encodes a human mago nashi protein in a biological sample comprising the steps of:

a) hybridizing the polynucleotide of claim 6 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and

b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding human mago nashi protein in said biological sample.
<table>
<thead>
<tr>
<th>11</th>
<th>20</th>
<th>29</th>
<th>38</th>
<th>47</th>
<th>56</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAC</td>
<td>TGC</td>
<td>AAG</td>
<td>GNG</td>
<td>CCG</td>
<td>GGG</td>
</tr>
<tr>
<td>ACG</td>
<td>GAC</td>
<td>TTG</td>
<td>GCT</td>
<td>GCG</td>
<td>TTT</td>
</tr>
<tr>
<td>TGG</td>
<td>GCG</td>
<td>GGC</td>
<td>TTC</td>
<td>CCG</td>
<td>GGT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>65</th>
<th>74</th>
<th>83</th>
<th>92</th>
<th>101</th>
<th>110</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACA</td>
<td>AAA</td>
<td>ATG</td>
<td>GCT</td>
<td>GTG</td>
<td>GCT</td>
</tr>
<tr>
<td>AGC</td>
<td>GAT</td>
<td>TAC</td>
<td>CTG</td>
<td>TAC</td>
<td>TAC</td>
</tr>
<tr>
<td>GGA</td>
<td>CAC</td>
<td>AAG</td>
<td>GAG</td>
<td>CTT</td>
<td>GTC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>119</th>
<th>128</th>
<th>137</th>
<th>146</th>
<th>155</th>
<th>164</th>
</tr>
</thead>
<tbody>
<tr>
<td>GGC</td>
<td>AAG</td>
<td>TTT</td>
<td>GGG</td>
<td>CAC</td>
<td>GAG</td>
</tr>
<tr>
<td>TTG</td>
<td>CTG</td>
<td>GAG</td>
<td>TTC</td>
<td>GAA</td>
<td>TTG</td>
</tr>
<tr>
<td>CGG</td>
<td>CCG</td>
<td>GAC</td>
<td>GGA</td>
<td>AAG</td>
<td>CTT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>173</th>
<th>182</th>
<th>191</th>
<th>200</th>
<th>209</th>
<th>218</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGA</td>
<td>TAT</td>
<td>GCC</td>
<td>AAC</td>
<td>AAC</td>
<td>AGC</td>
</tr>
<tr>
<td>AGC</td>
<td>AAT</td>
<td>TAC</td>
<td>AAA</td>
<td>AAT</td>
<td>GAT</td>
</tr>
<tr>
<td>GTG</td>
<td>ATG</td>
<td>ATC</td>
<td>AGA</td>
<td>AAA</td>
<td>GAG</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>227</th>
<th>236</th>
<th>245</th>
<th>254</th>
<th>263</th>
<th>272</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAT</td>
<td>GTG</td>
<td>CAC</td>
<td>AAG</td>
<td>AGT</td>
<td>GTA</td>
</tr>
<tr>
<td>AGA</td>
<td>GAA</td>
<td>CTG</td>
<td>AAG</td>
<td>AGA</td>
<td>ATT</td>
</tr>
<tr>
<td>ATT</td>
<td>GAT</td>
<td>GAC</td>
<td>AGT</td>
<td>GAA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>281</th>
<th>290</th>
<th>299</th>
<th>308</th>
<th>317</th>
<th>326</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATT</td>
<td>ACA</td>
<td>AAA</td>
<td>GAA</td>
<td>GAT</td>
<td>GAC</td>
</tr>
<tr>
<td>GAT</td>
<td>GCT</td>
<td>TTG</td>
<td>TGG</td>
<td>CCT</td>
<td>CCC</td>
</tr>
<tr>
<td>CCT</td>
<td>GAT</td>
<td>AGG</td>
<td>GTT</td>
<td>GGC</td>
<td>CGN</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>335</th>
<th>344</th>
<th>353</th>
<th>362</th>
<th>371</th>
<th>380</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAG</td>
<td>CTT</td>
<td>GAA</td>
<td>ATT</td>
<td>GTA</td>
<td>ATT</td>
</tr>
<tr>
<td>GAT</td>
<td>GAG</td>
<td>CAC</td>
<td>ATA</td>
<td>TCT</td>
<td>TTT</td>
</tr>
<tr>
<td>ACC</td>
<td>ACA</td>
<td>TCA</td>
<td>AAA</td>
<td>ATA</td>
<td>ELEI</td>
</tr>
</tbody>
</table>

**FIGURE 1A**
FIGURE 1B
FIGURE 2
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

<table>
<thead>
<tr>
<th>IPC</th>
<th>C12N15/12</th>
<th>C12N15/11</th>
<th>C12N15/70</th>
<th>C12N1/21</th>
<th>C12Q1/68</th>
</tr>
</thead>
<tbody>
<tr>
<td>C07K</td>
<td>C07K14/47</td>
<td>C07K16/18</td>
<td>A61K38/17</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

<table>
<thead>
<tr>
<th>IPC</th>
<th>C07K</th>
<th>C12N</th>
<th>C12Q</th>
<th>A61K</th>
</tr>
</thead>
</table>

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>HILLIER L. ET AL.: &quot;AC P50606&quot; EMBL DATABASE, 1 October 1996, HEIDELBERG, XP002065836 see the whole document</td>
<td>1-10,12</td>
</tr>
<tr>
<td>A</td>
<td>WO 94 08037 A (UNIV YALE ;MEDICAL RES COUNCIL (GB); ARTAVANIS TSAKONAS SPYRIDON () 14 April 1994 see the whole document</td>
<td>1-17</td>
</tr>
<tr>
<td>A</td>
<td>WO 96 11260 A (UNIV LELAND STANFORD JUNIOR) 18 April 1996 see the whole document</td>
<td>1-17</td>
</tr>
<tr>
<td>P,X</td>
<td>ADAMS M. ET AL.: &quot;AC AA307757&quot; EMBL DATABASE, 18 April 1997, HEIDELBERG, XP002065837 see the whole document</td>
<td>1-10,12</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

X Patent family members are listed in annex.

* Special categories of cited documents:
  *"A" document defining the general state of the art which is not considered to be of particular relevance
  *"E" earlier document but published on or after the international filing date
  *"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *"O" document referring to an oral disclosure, use, exhibition or other means
  *"P" document published prior to the international filing date but later than the priority date claimed

*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*"Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

*"a"* document member of the same patent family

Date of the actual completion of the international search

26 May 1998

Date of mailing of the international search report

0 3. 07. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx: 31 651 epo nl
Fax: (+31-70) 340-3018

Authorized officer

Kania, T
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>P,X</td>
<td>NATIONAL CANCER INSTITUTE: &quot;AC aa564400&quot; EMBL DATABASE, 11 September 1997, HEIDELBERG, XP002065838 see the whole document</td>
<td>1-10,12</td>
</tr>
<tr>
<td>P,X</td>
<td>WO 98 04590 A (MILLENIUM PHARMACEUTICALS INC) 5 February 1998 * see the whole document, esp. figures 1 and 4, embodiments *</td>
<td>1-17</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box I  Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. x Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

   Although claims 15,16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. □ Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. □ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II  Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>EP 0804548 A</td>
<td>05-11-1997</td>
</tr>
</tbody>
</table>